TOP TEN perturbations for NM_000395 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000395
Selected probe(set): 205159_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000395 (205159_at) across 5392 perturbations tested by GENEVESTIGATOR:

hCMV study 1 (CD69+) / uninfected CD4 T-LGL sample (diseased)

Relative Expression (log2-ratio):5.558487
Number of Samples:4 / 3
Experimental hCMV study 1 (CD69+)
CD69+ human cytomegalovirus (hCMV)-stimulated monoclonal CD4+ T-large granular lymphocytes (T-LGL) from peripheral blood of patients with monoclonal T-cell receptor (TCR)-alphabeta(+)/CD4(+) T-large granular lymphocyte (LGL) lymphocytosis.
Control uninfected CD4 T-LGL sample (diseased)
Unstimulated monoclonal CD4+ T-large granular lymphocytes (T-LGL) from peripheral blood of patients with monoclonal T-cell receptor (TCR)-alphabeta(+)/CD4(+) T-large granular lymphocyte (LGL) lymphocytosis.

lung adenocarcinoma study 9 (metastase; lymph node) / lung adenocarcinoma study 9 (metastase; brain)

Relative Expression (log2-ratio):5.4722233
Number of Samples:3 / 6
Experimental lung adenocarcinoma study 9 (metastase; lymph node)
Metastatic tumor tissue obtained from the lymph node of patients with primary lung adenocarcinoma.
Control lung adenocarcinoma study 9 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary lung adenocarcinoma.

precursor-B-ALL study 2 (E2A-PBX1) / T-ALL study 2

Relative Expression (log2-ratio):5.095951
Number of Samples:2 / 13
Experimental precursor-B-ALL study 2 (E2A-PBX1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control T-ALL study 2
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Dutch Childhood Oncology Group (DCOG).

Crohn's disease study 3 (baseline; non-responder; colon) / normal colon mucosa tissue

Relative Expression (log2-ratio):4.9149323
Number of Samples:7 / 6
Experimental Crohn's disease study 3 (baseline; non-responder; colon)
Colonic mucosal biopsies derived from Crohn's disease patients who are non-responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal colon mucosa tissue
Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening.

Crohn's disease study 10 / colorectal cancer study 13 (tvvad)

Relative Expression (log2-ratio):4.3582897
Number of Samples:4 / 3
Experimental Crohn's disease study 10
Colon biopsies derived from patients with Crohn's disease.
Control colorectal cancer study 13 (tvvad)
Colon biopsies derived from patients with low grade tubulovillous/villous adenoma.

ulcerative colitis study 5 (baseline; non-responder) / normal colon mucosa tissue

Relative Expression (log2-ratio):4.2364817
Number of Samples:16 / 6
Experimental ulcerative colitis study 5 (baseline; non-responder)
Colonic mucosal biopsies derived from ulcerative colitis patients who are non-responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal colon mucosa tissue
Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening.

precursor-B-ALL study 3 (E2A-PBX1) / T-ALL study 3

Relative Expression (log2-ratio):4.2147713
Number of Samples:6 / 29
Experimental precursor-B-ALL study 3 (E2A-PBX1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control T-ALL study 3
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Crohn's disease study 10 / colorectal cancer study 14 (tvvad)

Relative Expression (log2-ratio):3.7314348
Number of Samples:4 / 2
Experimental Crohn's disease study 10
Colon biopsies derived from patients with Crohn's disease.
Control colorectal cancer study 14 (tvvad)
Colon biopsies derived from patients with high grade tubulovillous/villous adenoma.

Crohn's disease study 3 (infliximab; 5mg/kg; responder; colon) / Crohn's disease study 3 (infliximab; 5mg/kg; non-responder; colon)

Relative Expression (log2-ratio):-3.60285
Number of Samples:11 / 7
Experimental Crohn's disease study 3 (infliximab; 5mg/kg; responder; colon)
Colonic mucosal biopsies from Crohn's disease patients who are responders to infliximab treatment, taken after the first intravenous infusion of 5 mg infliximab per kg body weight. Biopsies were taken 4 weeks after the first infliximab infusion in case of a single infusion and at 6 weeks if patients received a loading dose of infliximab at weeks 0, 2 and 6. The response to infliximab was assessed at 4 to 6 weeks after the first infliximab treatment, respectively. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication. ATC code:
Control Crohn's disease study 3 (infliximab; 5mg/kg; non-responder; colon)
Colonic mucosal biopsies from Crohn's disease patients who are non-responders to infliximab treatment, taken after the first intravenous infusion of 5 mg infliximab per kg body weight. Biopsies were taken 4 weeks after the first infliximab infusion in case of a single infusion and at 6 weeks if patients received a loading dose of infliximab at weeks 0, 2 and 6. The response was assessed at 4 to 6 weeks after the first infliximab treatment, respectively. The response to infliximab was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication. ATC code:

ulcerative colitis study 11 / colorectal cancer study 13 (tvvad)

Relative Expression (log2-ratio):3.5684862
Number of Samples:3 / 3
Experimental ulcerative colitis study 11
Colon biopsies derived from patients with ulcerative colitis.
Control colorectal cancer study 13 (tvvad)
Colon biopsies derived from patients with low grade tubulovillous/villous adenoma.